BioSpace News Archive

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) today announced that the Company will present at the 2023 BIO International Convention taking place in Boston, Mass. from June 5-8, 2023.

NewAmsterdam Pharma Company N.V. announced that it will present full data from ROSE2, a Phase 2 clinical trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy, in a late-breaking presentation at the National Lipid Association Scientific Sessions, being held June 1-4 in Atlanta, Georgia.

Ocean Biomedical (NASDAQ: OCEA ) announced today that its Scientific Co-founder, Dr. Jack A. Elias, MD, has been issued a broad patent for his cancer immunotherapy discovery related to reversing immune system suppression by binding chitinase 3-like-1 (CHi3L1) polypeptides with Ocean Biomedical’s proprietary immunoglobulin antibody.

Talis Biomedical Corporation, a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, announced Heiner Dreismann has joined its board of directors, effective immediately.

Poseida Therapeutics, Inc. today announced that the Company’s President of Gene Therapy, Brent Warner will participate in a virtual fireside chat at the Stifel 2023 Tailoring Genes.

Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, is proud to announce the release of the Glassless Flat Panel Detector from Konica Minolta on our SONIALVISION G4 LX and FLUOROspeed X1.

Artivion, Inc. (NYSE: AORT) today announced that the U.S. Food and Drug Administration (FDA) granted premarket application (PMA) approval of PERCLOT Absorbable Hemostatic System (“PerClot”) for use to control bleeding in certain open and laparoscopic surgical procedures.

Avantor, Inc. released its 2023 Sustainability Report, highlighting progress made in 2022 implementing environment, social & governance practices, in alignment with the company’s mission to set science in motion to create a better world.

Paragon 28, Inc. is pleased to announce the launch of its Gorilla® Supramalleolar Osteotomy Plating and PRESERVE™ SMO Allograft System which were developed to provide surgeons versatility in plate selection and surgical approach for supramalleolar osteotomies.

Vega Therapeutics , Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for VGA039 for the treatment of the rare bleeding disorder, von Willebrand disease (VWD).